The Arf6 pathway may also boost the drug resistance
of breast cancer cells, and Hashimoto et al. found that inhibiting Rab11b, or a component
of the Arf6 pathway called EPB41L5, increased the sensitivity
of MDA - MB - 231 cells to two different
cytotoxic compounds.